/R E M I N D E R — Media Advisory – Prime Minister’s itinerary for Sunday, June 2, 2024/
OTTAWA, ON, June 1, 2024 /CNW/ – Note: All times local National Capital Region, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
/R E M I N D E R — Media Advisory – Deputy Prime Minister’s itinerary for Sunday, June 2, 2024/
OTTAWA, ON, June 1, 2024 /CNW/ – Note: All times local. Toronto, Ontario Private meetings. 12:30 p.m. The Deputy Prime Minister will tour a cultural centre and make an announcement. She will be joined by the Minister for Women and Gender Equality and Youth, Marci Ien. A media availability
Sunvozertinib’s Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins.An ongoing randomized global Phase III study (WU-KONG28) is assessing sunvozertinib versus platinum containing doublets i
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel dr
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabol
Canadian Association of Journalists celebrates excellence in Canadian journalism from the past year at annual awards gala
TORONTO, June 1, 2024 /CNW/ – The Canadian Association of Journalists (CAJ) was pleased to acknowledge and celebrate the recipients of this year’s CAJ Awards for outstanding investigative journalism at an awards gala held earlier this evening at Toronto’s historic Reference Library
‘A Red Cross for Journalism’: Committee to Protect Journalists awarded Canadian Association of Journalists’ 2024 Charles Bury Award
TORONTO, June 1, 2024 /CNW/ – The Canadian Association of Journalists (CAJ) has awarded this year’s prestigious Charles Bury Award to the Committee to Protect Journalists (CPJ) for their continued commitment to ensuring the safety and security of journalists working in some of the most d
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with c
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and me
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and
